Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

Additionally, the trial met key secondary endpoints. The objective response rate was 67.7% in the pembrolizumab plus enfortumab vedotin arm compared with 44.4% in the chemotherapy arm (P <.00001).

Enfortumab vedotin plus pembrolizumab also significantly prolonged OS with a median OS of 31.5 months vs 16.1 months for chemotherapy, reducing the risk of death by 53% (HR, 0.47; 95% CI, 0.38-0. ...

Source Reference: Hoimes CJ, et al "Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer" J Clin Oncol 2022; DOI: 10.1200/JCO.22.01643.

“Enfortumab vedotin is the first drug, beyond chemotherapy and immunotherapy, to show a significant survival advantage in previously treated advanced urothelial cancer,” Powles said.